NCT05039866
Long-Term Follow-up of Subjects Who Were Treated With ST-920
Enrolling by Invitation
Not specifiedAges 18+ObservationalSangamo Therapeutics
~48 participants
Updated 2025-05-25 on ClinicalTrials.gov
What's tested:ST-920
At a glance
Recruiting sites
0 of 13 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
To evaluate long-term safety of ST-920
Measured over 4 years
Conditions
Where it's being run
13 sites across 12 statesUnited Kingdom2
California1
Florida1
Georgia1
Iowa1
Minnesota1
New York1
Ohio1
Study leadership
- Medical Monitor · STUDY_DIRECTOR · Sangamo Therapeutics, Inc.
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Subjects who received ST-920 therapy in a separate parent trial
Subjects who have consented to participate in this LTFU study.
What this trial measures
- To evaluate long-term safety of ST-9204 years
To evaluate long-term safety of ST-920 by assessment of incidence and severity of adverse events (AEs)